Proof-of-concept Study of BI 655130 add-on Treatment in Patients With Mild-to-moderately Active Ulcerative Colitis During TNF Inhibitor Therapy
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs BI 655130 (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 26 Jun 2017 Planned End Date changed from 18 May 2018 to 20 Jul 2018.
- 26 Jun 2017 Planned primary completion date changed from 6 Oct 2017 to 8 Dec 2017.
- 20 Jun 2017 Status changed from not yet recruiting to recruiting.